•
Dec 31, 2022
Sera Prognostics Q4 2022 Earnings Report
Announced financial results for the fourth quarter and full year 2022 ended December 31, 2022.
Key Takeaways
Sera Prognostics reported fourth quarter 2022 revenue of $65,000, compared to $26,000 for the same period in 2021. The net loss for the fourth quarter of 2022 was $9.7 million, compared to $12.5 million for the same quarter a year ago.
Announced positive top-line results from the AVERT PRETERM TRIAL.
Announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT.
Validated preeclampsia risk predictor, with results made available publicly.
Surpassed the required 2,800 PRIME study subject enrollment, which enables the interim look analysis by year end.
Sera Prognostics
Sera Prognostics
Forward Guidance
No specific forward guidance was provided in the press release.